Literature DB >> 25844596

Revision anterior cruciate ligament reconstruction with bone-patellar tendon-bone allograft and extra-articular iliotibial band tenodesis.

Randy Mascarenhas1, Mark O McConkey, Brian Forsythe, Christopher D Harner.   

Abstract

Revision anterior cruciate ligament (ACL) reconstruction is a technically demanding procedure with outcomes that generally fail to reach those seen with primary ACL reconstruction. With most index procedures using autograft tissue, it is not uncommon for allograft tissue to be required for revision ACL reconstruction. Compared with autografts, allografts take longer to incorporate and lead to more episodes of instability. In this article, we describe ipsilateral iliotibial band tenodesis performed to augment use of bone-patellar tendon-bone allograft in revision ACL reconstruction. This technique adds rotational stability to protect the allograft tissue while it incorporates.

Entities:  

Mesh:

Year:  2015        PMID: 25844596

Source DB:  PubMed          Journal:  Am J Orthop (Belle Mead NJ)        ISSN: 1078-4519


  3 in total

1.  Reply to the Letter to the Editor: Does Combined Intra- and Extraarticular ACL Reconstruction Improve Function and Stability? A Meta-analysis.

Authors:  Fernando Cury Rezende; Vinicius Ynoe de Moraes; Marcus Vinícius Luzo; Carlos Eduardo da Silveira Franciozi; João Carlos Belloti
Journal:  Clin Orthop Relat Res       Date:  2016-02-16       Impact factor: 4.176

2.  Good mid-term outcomes and low rates of residual rotatory laxity, complications and failures after revision anterior cruciate ligament reconstruction (ACL) and lateral extra-articular tenodesis (LET).

Authors:  Alberto Grassi; Juan Pablo Zicaro; Matias Costa-Paz; Kristian Samuelsson; Adrian Wilson; Stefano Zaffagnini; Vincenzo Condello
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2019-07-19       Impact factor: 4.342

3.  CORR Insights ® : Anterolateral Ligament of the Knee Shows Variable Anatomy in Pediatric Specimens.

Authors:  John P Albright
Journal:  Clin Orthop Relat Res       Date:  2017-02-28       Impact factor: 4.176

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.